MedTrace Logo

FOLFIRI as Salvage Treatment in Metastatic Biliary Tract Cancer (BTC) Patients Who Were Failed After Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study

NCT03110510 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2022-06-15

No results posted yet for this study

Summary

FOLFIRI as a salvage treatment in metastatic biliary tract cancer (BTC) patients who failed gemcitabine containing chemotherapy

Conditions

  • Biliary Tract Cancer

Interventions

DRUG

Fluorouracil

5FU 400mg/m2 bolus and then 2400mg/m2, continuous infusion D1-2

DRUG

Irinotecan Hydrochloride

Irinotecan 180 mg/m2

DRUG

leucovorin calcium

Leucovorin 200 mg/m2

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • joonoh park · SamsungMedicalCenter

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-06
Primary Completion
2019-09-06
Completion
2019-09-06

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03110510 on ClinicalTrials.gov